ERBB2 and cancer: Moreover, the combination of improved HER2 avidity and the slightly higher binding affinity of pertuzumab compared with trastuzumab makes it an appealing monoclonal antibody for therapies involving the transportation of potent cytotoxic agents to cancer cells overexpressing target receptors, such as in ADC (Antibody Drug Conjugate) treatments.